Relay Therapeutics, Inc.
RLAY
Kedudukan dalam Saham
#4221
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$17.16
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.76B
Perubahan (1 hari)
5.41%
Perubahan (1 tahun)
140.34%
Negara
US
Perdagangan Relay Therapeutics, Inc. (RLAY)
Kategori
Healthcare
Pendapatan untuk Relay Therapeutics, Inc. (RLAY)
Pendapatan pada Jun 2026 TTM: $-286.04M
Menurut laporan kewangan terkini Relay Therapeutics, Inc., pendapatan semasa syarikat ialah $-286.04M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-341.97M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-290.51M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Relay Therapeutics, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-286.04M | -15.30% |
| 2024 | $-337.71M | -1.25% |
| 2023 | $-341.97M | 17.72% |
| 2022 | $-290.51M | -20.16% |
| 2021 | $-363.87M | 594.25% |
| 2020 | $-52.41M | -30.40% |
| 2019 | $-75.31M | 54.36% |
| 2018 | $-48.79M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,944.13% |
US
|
|
| $-3.09B | 979.23% |
US
|
|
| $-4.02B | 1,304.08% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -781.96% |
NL
|
